Literatura korištena u prezentaciji i prikazu bolesnika poređana abecednim redom:
Baykan B, Martinez-Juarez IE, Altindag EA, et al. Lifetime prognosis of juvenile myoclonic epilepsy. Epil&Behav 2013; 28:18–24.
Berg AT, Berkovic SF, Brodie MJ et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010; 51(4):676–685.
Berkovic SF, Howell RA, Hay DA, Hopper JL. Epilepsies in twins: genetics of the major epilepsy syndromes. Ann. Neurol. 43: 435-445, 1998.
Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
Crespel A, Gelisse P, Reed R, et al. Management of juvenile myoclonic epilepsy. Epil&Behav 2013; 28:81–86.
Camfield CS, Camfield PR. Juvenile myoclonic epilepsy 25 years after seizure
onset: a population-based study. Neurology 2009;73(13):1041-5.
Camfield CS, Striano P, Camfield PR. Epidemiology of juvenile myoclonic epilepsy. Epil& Behav 2013; 28:15-17.
Delgado-Escueta AV. Advances in genetics of juvenile myoclonic epilepsies. Epilepsy Curr 2007; 7(3): 61-67.
Gelisse P, Genton P, Thomas P, Rey M, Samuelian JC, Dravet C. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 2001;70:240–3.
Genton P, Gelisse P, Thomas P. Juvenile myoclonic epilepsy today: current definitions and limits. In: Schmitz B, Sander T, editors. Juvenile myoclonic epilepsy: the Janz syndrome. Petersfield: Wrightson Biomedical Publishing; 2000, p.11–32.
Genton P, Thomas P, Kasteleijn-Nolst Trenité DGA et al. Clinical aspects of juvenile myoclonic epilepsy. Epil&Behav 2013; 28:8-14.
Janz, D.Beck-Mannagetta, G.Sander, T. Do idiopathic generalized epilepsies share a common susceptibility gene?. Neurology. 1992;42:48–55.
Martinez-Juarez IE, Alonso ME, Medina MT, et al. Juvenile myoclonic epilepsy subsyndromes: Family studies and long-term follow-up. Brain 2006;129:1269-80.
Pal DG, Evgrafov OV, Tabares P, et al. BRD2(RING3) is a probable major susceptibility gene for common juvenile myoclonic epilepsy. Am J Hum Genet 2003; 73: 261-270.
Panayiotopoulos CP, Obeid T, Waheed G. Absences in juvenile myoclonic epilepsy: a clinical and video-electroencephalographic study. Ann Neurol 1989;25:391-7.
Pedersen SB, Petersen KA. Juvenile myoclonic epilepsy: clinical and EEG features. Acta Neurol Scand 1998;97:160-3.
Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002;43:697–702.
Reimers A. New antiepileptic drugs and women. Seizure 2014; 23(8):585-591.
Senf P. Schmitz B. Holtkamp M. Janz D. Prognosis of Juvenile myoclonic epilepsy 45 years after seizure onset: Seizure Outcome and Predictors. Neurology 2013;81:2128-2133.
Sousa NAC, Sousa PS, Garzon E, et al. Juvenile myoclonic epilepsy: analysis of factors implied in delayed diagnosis and prognosis after clinical and electroencephalographical characterization. J Epilepsy Clin Neurophysiol 2005;11:7-13.
Suzuki T, Delgado-Escueta AV, Aguan K, et al. Mutation in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet 2004; 36:843-849.
Tracy Glauser T, Ben-Menachem E, Bourgeois B et al. for the ILAE subcommission of AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy
and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2012; 53(12):2091–2098.
Wandschneider B, Thompson PJ, Vollmar C, Koepp JM. Frontal lobe function and structure in juvenile myoclonic epilepsy: A comprehensive review of neuropsychological and imaging data Epilepsia 2012;53(12):2091–2098.
Woermann FG, Free SL, Koepp MJ, et al. Abnormal cerebral structure in juvenile myoclonic epilepsy demonstrated with voxel-based analysis of MRI. Brain 1999; 122:2101-8.
